Respiratory diseases such as Asthma and Chronic Obstructive Pulmonary Disease (COPD) are on the rise partly because of ...
The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...
The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the ...
Amgen and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic ...
As Delhi-NCR braces for another Diwali under a haze of toxic smog, Dr Ravi Shekhar Jha from Fortis Hospital, Faridabad, ...
Receiving dupilumab for 52 weeks lowered the risk for severe exacerbations vs. placebo in adults with COPD and type 2 ...
The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.
High-dose fluticasone increases sputum bacterial load in severe COPD; ICS withdrawal is poorly tolerated, highlighting ...
AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...
Select your location to view local American Lung Association events and news near you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback